Horizon Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.05M Buy
4,157
+419
+11% +$90.1K 0.13% 63
2026
Q1
$813K Buy
3,738
+8
+0.2% +$1.77K 0.12% 64
2025
Q4
$852K Buy
3,730
+5
+0.1% +$1.14K 0.13% 54
2025
Q3
$863K Buy
3,725
+89
+2% +$18.1K 0.13% 51
2025
Q2
$675K Sell
3,636
-106
-3% -$19.7K 0.12% 48
2025
Q1
$784K Buy
3,742
+117
+3% +$22.7K 0.13% 38
2024
Q4
$644K Buy
3,625
+158
+5% +$29K 0.11% 42
2024
Q3
$685K Buy
3,467
+13
+0.4% +$2.43K 0.14% 39
2024
Q2
$592K Sell
3,454
-54
-2% -$8.95K 0.14% 35
2024
Q1
$639K Buy
3,508
+111
+3% +$19.1K 0.17% 34
2023
Q4
$526K Sell
3,397
-19
-0.6% -$2.77K 0.15% 38
2023
Q3
$509K Buy
3,416
+16
+0.5% +$2.35K 0.2% 34
2023
Q2
$458K Buy
3,400
+16
+0.5% +$2.35K 0.18% 37
2023
Q1
$539K Buy
3,384
+16
+0.5% +$2.45K 0.4% 31
2022
Q4
$544K Sell
3,368
-138
-4% -$21.2K 0.44% 27
2022
Q3
$471K Sell
3,506
-1,544
-31% -$222K 0.35% 31
2022
Q2
$773K Buy
5,050
+804
+19% +$123K 0.32% 41
2022
Q1
$688K Buy
4,246
+13
+0.3% +$1.89K 0.21% 44
2021
Q4
$573K Buy
+4,233
New +$500K 0.17% 52

Other funds holding ABBV

Horizon Wealth Management's ABBV Position: Q2 2026 in Review

Horizon Wealth Management increased its AbbVie (ABBV) stake by 11% in Q2 2026, buying an estimated $90.1K and bringing the position to 4,157 shares worth $1.05M. The position accounts for 0.13% of the portfolio, ranked #63.

Horizon Wealth Management first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Horizon Wealth Management held 4,157 shares of AbbVie worth $1.05M as of Q2 2026.
  • Horizon Wealth Management bought 419 AbbVie shares in Q2 2026, an estimated $90.1K.
  • AbbVie made up 0.13% of Horizon Wealth Management's portfolio in Q2 2026, its #63 holding.
  • Horizon Wealth Management first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
  • 4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Horizon Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.